- Home
- CNF vs TELA Comparison
CNF vs TELA Comparison
Compare CNF & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | TELA |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 31.4M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNF | TELA |
|---|---|---|
| Price | $2.21 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 5.3K | ★ 287.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | $252.34 | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $2.04 | $0.50 |
| 52 Week High | $6.49 | $1.73 |
Technical Indicators
Market Signals| Indicator | CNF | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 57.44 |
| Support Level | $2.07 | $0.78 |
| Resistance Level | $2.35 | $0.96 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.09 | 62.18 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.